---
title: Reduce movement and mood problems
nct_id: NCT07625540
phase: NA
status: RECRUITING
sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07625540"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07625540"
last_fetched: "2026-06-04T14:00:19.414Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce movement and mood problems

**Goal (in five words):** Reduce movement and mood problems

**Official Title:** Study on the Efficacy and Safety of Subthalamic Nucleus (STN)-Targeted Transcranial Temporal Interference Stimulation (tTIS) for Motor and Non-Motor Symptoms in Parkinson's Disease (PD): A Randomized, Double-Blind, Controlled Exploratory Trial

**Trial ID:** [NCT07625540](https://clinicaltrials.gov/study/NCT07625540)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Target Enrollment:** 32 participants
- **Start Date:** 2026-05-20
- **Completion Date:** 2027-04
- **Conditions:** Parkinson's Disease (PD)
- **Interventions:** real transcranial temporal interference stimulation, sham transcranial temporal interference stimulation
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to ease motor problems like tremor, slowness, and stiffness and to help related non-motor issues such as sleep or mood by directly modulating the subthalamic nucleus, a deep brain region involved in Parkinson's symptoms. The approach, transcranial temporal interference stimulation or tTIS, applies two high-frequency currents at the scalp that intersect in the brain to create a low-frequency envelope at the subthalamic nucleus, changing its activity noninvasively; the trial compares real versus sham stimulation and is studied as an add-on to stable Parkinson medications rather than a replacement for levodopa. They are looking for people aged 50 to 85 with clinically established or probable Parkinson's disease at Hoehn and Yahr stage 2 or higher, on a stable anti-Parkinsonian regimen for at least four weeks and able to tolerate MRI, while excluding those with prior DBS or other implants, epilepsy, recent other brain stimulation, major cognitive or psychiatric problems, or pregnancy.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 85 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Aged 50-85 years, male or female.
* Diagnosed with "clinically established" or "clinically probable" Parkinson's disease according to the 2015 MDS Clinical Diagnostic Criteria for Parkinson's Disease.
* Hoehn-Yahr stage ≥ 2, and judged by the investigator to be able to cooperate in completing scale-based assessments and MRI examinations.
* Stable regimen of anti-Parkinsonian medication for at least 4 weeks before enrollment, and agreement to maintain a stable regimen during the main study phase unless medically necessary to change.
* Written informed consent signed by the study participant.

Exclusion Criteria:

* Non-primary Parkinson's disease or other parkinsonism / atypical parkinsonism.
* Previous receipt of invasive neuromodulation therapies such as deep brain stimulation (DBS) or other intracranial implantation/stereotactic brain surgery.
* Presence of contraindications or high-risk conditions for transcranial electrical stimulation (e.g., incompatible metal implants/implantable electrical stimulation devices, etc.), or judged by the investigator as unsuitable to receive transcranial electrical stimulation.
* Receipt of non-invasive neuromodulation interventions such as transcranial magnetic stimulation or transcranial electrical stimulation within the past six months.
* Presence of contraindications to MRI or inability to tolerate MRI examination.
* Significant cognitive impairment or severe psychiatric symptoms that prevent completion of assessments or result in poor compliance.
* New initiation or dose adjustment of medications or treatments that significantly affect sleep architecture/consciousness status within the past 4 weeks.
* History of epilepsy.
* Pregnancy or breastfeeding.
* Any other condition judged by the investigator as unsuitable for participation in the study.
```

## Locations (1)

- Shanghai General Hospital, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Xiaoying Zhu, MD — (CONTACT) — 86-13817659260 — docxiaoying@163.com
  - Jingtao Feng, MD — (CONTACT) — 86-18651285832 — fengjt0919@163.com

## Central Contacts

- Xiaoying Zhu, MD — (CONTACT) — 86-13817659260 — docxiaoying@163.com
- Jingtao Feng, MD — (CONTACT) — 86-18651285832 — fengjt0919@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07625540*  
*HTML version: https://parkinsonspathways.com/trial/NCT07625540*  
*Source data: https://clinicaltrials.gov/study/NCT07625540*